Writing and Amending the Clinical Protocol: IND and CTA Lifecycle Strategy for B-Cell Activating Factor and APRIL-Targeted Biologics in IgA Nephropathy

Immunoglobulin A (IgA) nephropathy is the most common primary glomerulonephritis worldwide and a leading cause of progressive chronic kidney disease, driven in substantial part by dysregulated mucosal B-cell activity supported by B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) (Lafayette & Kelepouris, 2022). Biologics that neutralize one or both of these cytokines represent a disease-modifying approach distinct from the nonspecific immunosuppression historically used in this condition. This article is written from the perspective of a clinical trial manager carrying a BAFF/APRIL-targeted biologic program from its initial Investigational New Drug (IND) application or Clinical Trial Application (CTA) through subsequent protocol amendments. It reviews the disease and mechanistic rationale, best practices for trial phase and population selection in a slowly progressive renal disease, anticipated risks and pharmacovigilance strategy, statistical sample-size rationale drawn from registered trials using a surrogate endpoint, the detailed regulatory requirements and timelines governing the initial submission and amendments across FDA, Health Canada, and EMA frameworks, a representative schedule of assessments spanning a twelve-month period, and the application of artificial intelligence tools to data capture and quality. The article closes with recommendations for regulatory affairs and clinical operations professionals managing this therapeutic category.Keywords: BAFF; APRIL; IgA nephropathy; protocol amendment; Investigational New Drug application; Clinical Trial Application; proteinuria surrogate endpoint; regulatory artificial intelligence